EP1501523A4 - Carbon monoxide as a biomarker and therapeutic agent - Google Patents

Carbon monoxide as a biomarker and therapeutic agent

Info

Publication number
EP1501523A4
EP1501523A4 EP02807413A EP02807413A EP1501523A4 EP 1501523 A4 EP1501523 A4 EP 1501523A4 EP 02807413 A EP02807413 A EP 02807413A EP 02807413 A EP02807413 A EP 02807413A EP 1501523 A4 EP1501523 A4 EP 1501523A4
Authority
EP
European Patent Office
Prior art keywords
biomarker
therapeutic agent
carbon monoxide
monoxide
carbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02807413A
Other languages
German (de)
French (fr)
Other versions
EP1501523A1 (en
Inventor
Augustine M K Choi
Leo E Otterbein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Johns Hopkins University
School of Medicine of Johns Hopkins University
Original Assignee
Yale University
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Yale University
Publication of EP1501523A1 publication Critical patent/EP1501523A1/en
Publication of EP1501523A4 publication Critical patent/EP1501523A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP02807413A 2002-05-09 2002-05-09 Carbon monoxide as a biomarker and therapeutic agent Withdrawn EP1501523A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/014836 WO2003094932A1 (en) 2002-05-09 2002-05-09 Carbon monoxide as a biomarker and therapeutic agent

Publications (2)

Publication Number Publication Date
EP1501523A1 EP1501523A1 (en) 2005-02-02
EP1501523A4 true EP1501523A4 (en) 2006-12-13

Family

ID=29418043

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02807413A Withdrawn EP1501523A4 (en) 2002-05-09 2002-05-09 Carbon monoxide as a biomarker and therapeutic agent

Country Status (13)

Country Link
EP (1) EP1501523A4 (en)
JP (1) JP2005532314A (en)
KR (1) KR20040106515A (en)
CN (1) CN1638781A (en)
AU (1) AU2002308676B2 (en)
BR (1) BR0215717A (en)
CA (1) CA2484770A1 (en)
EA (1) EA200401478A1 (en)
MX (1) MXPA04011113A (en)
NO (1) NO20044865L (en)
RS (1) RS96904A (en)
UA (1) UA84402C2 (en)
WO (1) WO2003094932A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US7011854B2 (en) 2002-02-04 2006-03-14 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
CA2481972A1 (en) 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating ileus
CA2481786A1 (en) 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
ATE521357T1 (en) * 2002-05-17 2011-09-15 Univ Yale METHOD FOR TREATING HEPATITIS
JP2005345242A (en) * 2004-06-02 2005-12-15 Tohoku Univ Evaluation method of chemotherapy medical treatment effect of lung cancer
JPWO2007073005A1 (en) * 2005-12-22 2009-06-04 学校法人慶應義塾 Methyl group transfer regulator
EP2099439A2 (en) * 2006-12-06 2009-09-16 Alfama - Investigação E Desenvolvimento De Produto Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
JP2010094122A (en) 2008-06-12 2010-04-30 Keio Gijuku Diagnosis-treatment option for head-and-neck tumor using micro-rna as biomarker
JP2012046470A (en) * 2010-08-30 2012-03-08 Japan Science & Technology Agency Enzyme activity inhibitor for gapdh
CA2824056C (en) * 2011-01-14 2019-01-08 Children's Hospital Los Angeles Solution of carbon monoxide for treatment of disease, including sickle cell disease
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
US9359197B2 (en) 2011-03-24 2016-06-07 Technion Research & Development Foundation Ltd. Method of diagnosing, prognosing and monitoring parkinson's disease
EP2699242B1 (en) 2011-04-19 2017-11-01 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
WO2013013179A1 (en) 2011-07-21 2013-01-24 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
US10031126B2 (en) 2013-04-04 2018-07-24 The Regents Of The University Of California System and method for utilizing exhaled breath for monitoring inflammatory states
EP2868348A1 (en) * 2013-11-04 2015-05-06 Universität Zürich CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair
TW201618795A (en) * 2014-04-15 2016-06-01 波泰里斯股份有限公司 Systems and methods to improve organ function and organ transplant longevity
JP7161737B2 (en) * 2017-01-30 2022-10-27 哲也 石川 Methods for testing malignant tumors
EP3804731A4 (en) * 2018-06-08 2022-04-06 Sumitomo Seika Chemicals Co., Ltd. Composition for skin wounds
CN112236150A (en) 2018-06-08 2021-01-15 住友精化株式会社 Composition for inflammatory digestive organ diseases
US20220296636A1 (en) * 2019-06-06 2022-09-22 The General Hospital Corporation Carbon Monoxide as a Treatment for Neurodegenerative Disease
US20230346831A1 (en) * 2020-07-16 2023-11-02 Cornell University Methods for treating metastatic cancer using low dose carbon monoxide
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882674A (en) * 1994-06-18 1999-03-16 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system comprising active substances representing carbon monoxide sources
WO2002078684A2 (en) * 2001-03-30 2002-10-10 Sangstat Medical Corporation Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
EP0921807B1 (en) * 1996-08-27 2003-11-05 Messer Griesheim GmbH Hydrogenous medicament

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882674A (en) * 1994-06-18 1999-03-16 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system comprising active substances representing carbon monoxide sources
WO2002078684A2 (en) * 2001-03-30 2002-10-10 Sangstat Medical Corporation Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
L.E. OTTERBEIN: "Carbon monoxide: innovative anti-inflammatory properties of an age-old gas molecule", ANTIOXIDANTS AND REDOX SIGNALING, vol. 4, no. 2, April 2002 (2002-04-01), pages 309 - 319, XP009068341 *
LEFER D J ET AL: "A comparison of vascular biological actions of carbon-monoxide and nitric-oxide", SCISEARCH, 1993, XP002960667 *
OTTERBEIN L E ET AL: "Carbon monoxide provides protection against hyperoxic lung injury", AMERICAN JOURNAL OF PHYSIOLOGY. LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, vol. 276, 1999, pages L688 - L694, XP002960664, ISSN: 1040-0605 *
See also references of WO03094932A1 *
SHAHIN ET AL.: "Carboxyhemoglobin in pediatric sepsis and the systemic inflammatory response syndrome", CLINICAL INTENSIVE CARE, vol. 11, no. 6, 2000, pages 311 - 317, XP009072820 *
THIEMERMANN C.: "Inhaled CO: deadly gas or novel therapeutic?", NATURE MEDICINE, vol. 7, no. 5, 2001, pages 534 - 535, XP002401894 *
VASSALLI F ET AL: "Inhibition of hypoxic pulmonary vasoconstriction by carbon monoxide in dogs", DRUGU, 1999, XP002960668 *
YUAN S ET AL: "Evidence of increased endogenous carbon monoxide production in newborn rat endotoxicosis", BIOSIS, 1998, XP002960665 *
ZEGDI ET AL.: "Increased endogenous CO prodution in severe sepsis", INTENSIVE CARE MEDICINE, vol. 23, 10 April 2002 (2002-04-10), pages 793 - 796, XP002401895 *

Also Published As

Publication number Publication date
AU2002308676A1 (en) 2003-11-11
JP2005532314A (en) 2005-10-27
NO20044865L (en) 2004-12-07
UA84402C2 (en) 2008-10-27
BR0215717A (en) 2005-02-22
CN1638781A (en) 2005-07-13
RS96904A (en) 2007-02-05
KR20040106515A (en) 2004-12-17
WO2003094932A1 (en) 2003-11-20
EA200401478A1 (en) 2005-12-29
MXPA04011113A (en) 2005-02-14
EP1501523A1 (en) 2005-02-02
AU2002308676B2 (en) 2009-06-11
CA2484770A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
EP1501523A4 (en) Carbon monoxide as a biomarker and therapeutic agent
EG23566A (en) Use of oxyhydroxide compounds for reducing carbon monoxide in the mainstram smoke of a cigarette
EP1671584A4 (en) Lancing unit and lancing apparatus
GB0310922D0 (en) Bed
AU2003297908A8 (en) Articulated elements and methods for use
AU2003233738A8 (en) Oxygen reduction catalyst
AU2003302013A8 (en) Therapeutic delivery of carbon monoxide
GB0228074D0 (en) Carbon dioxide absorption
GB2413963B (en) Improved airway device
GB0219660D0 (en) Therapeutic use
PL397022A1 (en) Therapeutic agent
GB0200941D0 (en) Laryngoscopes and parts thereof
GB0217391D0 (en) Improvements in activated carbon
GB2402890B (en) Systems and methods for carbon monoxide clean-up
GB2385331B (en) Modified carbon black
AU2003303654A8 (en) Carbon nanotubes
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
EP1569928A4 (en) Therapeutic compounds and methods
ZA200409035B (en) Carbon monoxide as a biomarker and therapeutic agent
GB0409376D0 (en) Therapeutic delivery of carbon monoxide
GB0228048D0 (en) Track set
EP1736544A4 (en) Gm1 PROMOTER AND USE THEREOF
GB2386099B (en) Support and dedicated pen assembly
GB2401786B (en) Portable baptistry
GB0228391D0 (en) Carbon monoxide shut off protection device

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: OTTERBEIN, LEO, E.

Inventor name: CHOI, AUGUSTINE, M., K.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1072179

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 19/02 20060101ALI20060630BHEP

Ipc: A61P 25/28 20060101ALI20060630BHEP

Ipc: A61P 17/02 20060101ALI20060630BHEP

Ipc: A61P 11/00 20060101ALI20060630BHEP

Ipc: A61K 33/00 20060101AFI20031126BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20061109

17Q First examination report despatched

Effective date: 20070404

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: CARBON MONOXIDE FOR USE TO TREAT LOCALIZED INFLAMMATION OF KIDNEY

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120322

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1072179

Country of ref document: HK